Ubs Group Ag Adagene Inc. Transaction History

Ubs Group Ag

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$2.12 - $3.24 $530 - $810	-250 Reduced 60.39%	164 $0
Q1 2024 May 13, 2024	BUY	$1.96 - $4.15 $809 - $1,713	413 Added 41300.0%	414 $1,000
Q4 2023 Feb 09, 2024	BUY	$1.31 - $1.93 $1 - $1	1 New	1 $0
Q4 2021 Feb 14, 2022	SELL	$7.4 - $14.44 $9,065 - $17,689	-1,225 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$12.7 - $20.68 $10,629 - $17,309	-837 Reduced 40.59%	1,225 $18,000
Q2 2021 Aug 13, 2021	BUY	$11.8 - $17.87 $21,063 - $31,897	1,785 Added 644.4%	2,062 $28,000
Q1 2021 May 12, 2021	BUY	$17.0 - $29.99 $4,709 - $8,307	277 New	277 $5,000

9.87M

Ticker ADAG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,423,200
Market Cap $87.3M
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.